Enterolactone-d6

• UNSPSC Description:

  Enterolactone-d6 is the deuterium labeled Enterolactone. Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity[1]. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis[2].

• Target Antigen:

  Apoptosis; Endogenous Metabolite; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Apoptosis;Metabolic Enzyme/Protease;Others

• Field of Research:

  Cancer

• Purity:

  95.0

• Solubility:

  DMSO : 30 mg/mL (ultrasonic;warming)

• Smiles:

  C([C@H]1[C@H](CC2=C(C(O)=C(C=C2[2H])[2H])[2H])C(=O)OC1)C3=C(C(O)=C(C=C3[2H])[2H])[2H]

• Molecular Weight:

  304.37

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Bigdeli B, et al. Enterolactone: A novel radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis. Toxicol Appl Pharmacol. 2016;313:180-194.|[3]Mali AV, et al. Enterolactone modulates the ERK/NF-κB/Snail signaling pathway in triple-negative breast cancer cell line MDA-MB-231 to revert the TGF-β-induced epithelial-mesenchymal transition. Cancer Biol Med. 2018;15(2):137-156.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  104411-11-2